Therefore, we set out to study the impact of apoC-III targeting on atherosclerosis using a combined approach of apoC-III ASO treatment and a cholesterol-lowering intervention, as this better resembles the current therapeutic approach. Here, APOC3 is linked to atherosclerosis.